DelMar Pharmaceuticals Profile


Odds of Distress

Analyze Filter    Fiscal Quarter End: December 31, 2019
Equity ratings for DelMar Pharmaceuticals are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting September 11, 2019 and ending today December 10, 2019. Click here to learn more.

DelMar Pharmaceuticals Profile

Next fiscal quarter end is expected on December 31, 2019. DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California. DelMar Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2 people. more
DelMar Pharmaceuticals Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
DelMar Pharmaceuticals SEC Filings
DelMar Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameDelMar Pharmaceuticals
President CEO, DirectorJeffrey BachaView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Healthcare, Biotechnology
InstrumentUSA Stock View All
LocationCalifornia; U.S.A
Business Address12707 High Bluff Drive
ExchangeBATS Exchange
Phone858 350 4364
CurrencyUSD - US Dollar
Next Fiscal Year EndJune 30, 2021
Most Recent QuarterSeptember 30, 2019
Last Fiscal Year EndJune 30, 2019
Date Short InterestNovember 15, 2019
DelMar Pharmaceuticals (DMPI) is traded on BATS Exchange in USA. It is located in 12707 High Bluff Drive and employs 2 people. DelMar Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with current market capitalization of 6.85 M. DelMar Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 8.73 M outstanding shares of which 330.62 K shares are currently shorted by private and institutional investors with about 0.49 trading days to cover. DELMAR PHARMA currently holds about 3.72 M in cash with (6.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Check DelMar Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

DelMar Pharmaceuticals Target Price Odds Analysis

Odds Below 0.6225HorizonTargetOdds Above 0.6225
49.74%30 days 0.62 50.16%
Based on normal probability distribution, the odds of DelMar Pharmaceuticals to move above current price in 30 days from now is about 50.16 (This DelMar Pharmaceuticals probability density function shows the probability of DelMar Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

DelMar Pharmaceuticals Top Holders

DelMar Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

DelMar Pharmaceuticals Key Fundamentals

DelMar Pharmaceuticals Against Markets

Did you try this?

Run Price Transformation Now


Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Module

DelMar Pharmaceuticals Upcoming and Recent Events

DelMar Pharmaceuticals Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportFebruary 10, 2020
Next Earnings ReportMay 20, 2020
Next Fiscal Quarter EndDecember 31, 2019
Next Fiscal Year EndSeptember 8, 2020
Last Quarter Report DateSeptember 30, 2019
Last Earning Anouncement DateDecember 31, 2018

DelMar Pharmaceuticals Corporate Filings

DelMar Pharmaceuticals SEC Reporting

Financial Statements and Exhibits. Other Events
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Unclassified Corporate Event
Other Events

DelMar Pharmaceuticals Corporate Directors

John Bell Independent Director
William Garner Director
Erich Mohr Independent Director
Additionally see Investing Opportunities. Please also try Premium Stories module to follow macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.